A combination therapy is helping attack cancer with a one-two punch. A study out of Switzerland finds adding the cancer drug Rituxan can increase survival rates in patients with Non-Hodgkin's Lymphoma.
The study found patients who got the drug along with standard Chemotherapy had an overall survival rate of 70%, compared to 54% among patients who just received Chemotherapy. The study in the New England Journal of Medicine adds this is the first new drug combination in 20 years to show an increase in overall survival in patients with Non-Hodgkin's Lymphoma.
Non-Hodgkin's Lymphoma affects approximately 1.5 million around the world, and is the 3rd fastest growing form of cancer behind Melanoma and Lung Cancer. NHL is a more common form of Blood Cancer than Leukemia and approximately 55% of cases of NHL are aggressive.